Gomekli treats adults and children (≥2 years) with NF1-related plexiform neurofibromas that can’t be fully removed. It inhibits MEK enzymes to slow tumor growth and reduce tumor size.
To Get Full Access :
To Get Full Access :
Gomekli treats adults and children (≥2 years) with NF1-related plexiform neurofibromas that can’t be fully removed. It inhibits MEK enzymes to slow tumor growth and reduce tumor size.
The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.
Molecule Name :
Innovator :
Approval Date :
NCE-1 Date :
NCE Date :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :





For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.